Cargando…
Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination
Deployment of the BNT162b2 mRNA Covid-19 Vaccine in Israel began in December 2020. This is a retrospective analysis of serological data, showing SARS-CoV-2 anti-S IgG kinetics in 116 Israeli health care workers receiving BNT162b2. Sero-conversion occurred in 14 days in all study participants, with I...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354802/ https://www.ncbi.nlm.nih.gov/pubmed/34393018 http://dx.doi.org/10.1016/j.vaccine.2021.08.025 |
_version_ | 1783736655668051968 |
---|---|
author | Grupel, Daniel Gazit, Sivan Schreiber, Licita Nadler, Varda Wolf, Tamar Lazar, Rachel Supino-Rosin, Lia Perez, Galit Peretz, Asaf Ben Tov, Amir Mizrahi-Reuveni, Miri Chodick, Gabriel Patalon, Tal |
author_facet | Grupel, Daniel Gazit, Sivan Schreiber, Licita Nadler, Varda Wolf, Tamar Lazar, Rachel Supino-Rosin, Lia Perez, Galit Peretz, Asaf Ben Tov, Amir Mizrahi-Reuveni, Miri Chodick, Gabriel Patalon, Tal |
author_sort | Grupel, Daniel |
collection | PubMed |
description | Deployment of the BNT162b2 mRNA Covid-19 Vaccine in Israel began in December 2020. This is a retrospective analysis of serological data, showing SARS-CoV-2 anti-S IgG kinetics in 116 Israeli health care workers receiving BNT162b2. Sero-conversion occurred in 14 days in all study participants, with IgG levels peaking approximately 30 days after initiation of the vaccination series. A statistically significant difference was observed in IgG levels between subjects younger than 50 years and older participants, although in all cases, IgG levels were well above the level considered reactive by the test's manufacturer. The importance of this difference needs to be studied further, but a potential difference in vaccine efficacy and vaccine effect length could possibly be present between these two groups. |
format | Online Article Text |
id | pubmed-8354802 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83548022021-08-11 Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination Grupel, Daniel Gazit, Sivan Schreiber, Licita Nadler, Varda Wolf, Tamar Lazar, Rachel Supino-Rosin, Lia Perez, Galit Peretz, Asaf Ben Tov, Amir Mizrahi-Reuveni, Miri Chodick, Gabriel Patalon, Tal Vaccine Short Communication Deployment of the BNT162b2 mRNA Covid-19 Vaccine in Israel began in December 2020. This is a retrospective analysis of serological data, showing SARS-CoV-2 anti-S IgG kinetics in 116 Israeli health care workers receiving BNT162b2. Sero-conversion occurred in 14 days in all study participants, with IgG levels peaking approximately 30 days after initiation of the vaccination series. A statistically significant difference was observed in IgG levels between subjects younger than 50 years and older participants, although in all cases, IgG levels were well above the level considered reactive by the test's manufacturer. The importance of this difference needs to be studied further, but a potential difference in vaccine efficacy and vaccine effect length could possibly be present between these two groups. Elsevier Ltd. 2021-09-07 2021-08-11 /pmc/articles/PMC8354802/ /pubmed/34393018 http://dx.doi.org/10.1016/j.vaccine.2021.08.025 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Short Communication Grupel, Daniel Gazit, Sivan Schreiber, Licita Nadler, Varda Wolf, Tamar Lazar, Rachel Supino-Rosin, Lia Perez, Galit Peretz, Asaf Ben Tov, Amir Mizrahi-Reuveni, Miri Chodick, Gabriel Patalon, Tal Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination |
title | Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination |
title_full | Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination |
title_fullStr | Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination |
title_full_unstemmed | Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination |
title_short | Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination |
title_sort | kinetics of sars-cov-2 anti-s igg after bnt162b2 vaccination |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354802/ https://www.ncbi.nlm.nih.gov/pubmed/34393018 http://dx.doi.org/10.1016/j.vaccine.2021.08.025 |
work_keys_str_mv | AT grupeldaniel kineticsofsarscov2antisiggafterbnt162b2vaccination AT gazitsivan kineticsofsarscov2antisiggafterbnt162b2vaccination AT schreiberlicita kineticsofsarscov2antisiggafterbnt162b2vaccination AT nadlervarda kineticsofsarscov2antisiggafterbnt162b2vaccination AT wolftamar kineticsofsarscov2antisiggafterbnt162b2vaccination AT lazarrachel kineticsofsarscov2antisiggafterbnt162b2vaccination AT supinorosinlia kineticsofsarscov2antisiggafterbnt162b2vaccination AT perezgalit kineticsofsarscov2antisiggafterbnt162b2vaccination AT peretzasaf kineticsofsarscov2antisiggafterbnt162b2vaccination AT bentovamir kineticsofsarscov2antisiggafterbnt162b2vaccination AT mizrahireuvenimiri kineticsofsarscov2antisiggafterbnt162b2vaccination AT chodickgabriel kineticsofsarscov2antisiggafterbnt162b2vaccination AT patalontal kineticsofsarscov2antisiggafterbnt162b2vaccination |